April 17, 2018
From the event website:
We hope you’ll join us in welcoming Will Siu, M.D., DPhil and Sara Reed, MS, MFT as they discuss their participation in an FDA-regulated clinical trial with MDMA – specifically their experiences as participants in the therapist training program. MDMA is commonly referred to as “molly” or “ecstasy” but substances sold by these names sometimes contain little to no MDMA.
Recent studies by the Multidisciplinary Association for Psychedelic Studies (MAPS) are demonstrating that MDMA shows great promise as a psychotherapeutic assistant in treating individuals with PTSD. Sara and Will participated in the therapist training program as preparation for their involvement as researchers and therapists in the upcoming trials using MDMA as an adjunct to therapy for PTSD. This event is sponsored by UConn Students for Sensible Drug Policy (SSDP) along with the Multidisciplinary Association of Psychedelic Studies (MAPS).